Hybrid Antimalarial Drug Design and Evaluation

Hybrid antimalarial drug design leverages the covalent linkage of two or more pharmacophores into a single molecule to achieve multipronged activity against Plasmodium parasites and to overcome resistance to existing therapies. By combining complementary mechanisms of action—such as inhibition of haem detoxification, interference with parasite metabolic pathways and mitigation of oxidative stress—hybrid compounds can display enhanced potency, reduced toxicity and prolonged half-life. Recent efforts have focused on quinoline-based scaffolds fused to other bioactive motifs, including natural products and heterocyclic rings, to target both blood-stage parasites and transmission stages. Evaluation pipelines employ in vitro assays against chloroquine-sensitive and resistant Plasmodium falciparum strains, in vivo rodent models to assess efficacy and safety, and in silico methods such as quantitative structure–activity relationship (QSAR) modelling and ADMET predictions to guide optimisation. These integrated approaches have yielded hybrids that not only suppress parasitaemia in murine models at nanomolar doses but also exhibit antioxidant or immunomodulatory properties that may ameliorate malaria pathology. The global significance of this research is underscored by the continued burden of malaria in endemic regions and the threat of artemisinin resistance; hybrid molecules thus represent a next-generation strategy with the potential to reinvigorate antimalarial pipelines and support eradication goals.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Hybrid Antimalarial Drug Design and Evaluation publication trend

The graph below shows the total number of articles in hybrid antimalarial drug design and evaluation across all publications each year (not limited to Nature Index journals).

Technical terms

Hybrid pharmacophore: A single molecule formed by covalently linking two or more active chemical scaffolds to combine their biological activities.

β-Hematin formation: The biomineralisation process wherein free haem released by the parasite is converted into non-toxic crystalline hemozoin; its inhibition disrupts parasite detoxification.

QSAR (Quantitative Structure–Activity Relationship): A computational modelling technique that correlates chemical structure features with biological activity to predict and optimise compound potency.

ADMET: An acronym for Absorption, Distribution, Metabolism, Excretion and Toxicity, encompassing the pharmacokinetic and safety properties of a drug candidate.

References

1. Antimalarial and antioxidant activities of novel artesunate-ellagic acid hybrid compound in vitro and in vivo. Frontiers in Pharmacology (2024).
2. Synthesis, Antimalarial, Antileishmanial, and Cytotoxicity Activities and Preliminary In Silico ADMET Studies of 2-(7-Chloroquinolin-4-ylamino)ethyl Benzoate Derivatives. Pharmaceuticals (2023).
3. Design, Synthesis, Antitumor, and Antiplasmodial Evaluation of New 7-Chloroquinoline–Benzimidazole Hybrids. Molecules (2024).